StocksMedium•12 October 2026•
1 min read
Contineum Therapeutics Shares Plunge 29% Following BMS Trial Results
Key Facts
1Contineum Therapeutics shares dropped 29% on Monday following clinical trial results from partner Bristol Myers Squibb.
2Analysts highlight long-term potential for PIPE-791 in idiopathic pulmonary fibrosis despite the negative market reaction.
Contineum Therapeutics shares dropped 29% on Monday, October 12, 2026, following the release of clinical trial results from its partner, Bristol Myers Squibb. Benzinga reported that the significant sell-off was triggered by the market's reaction to the trial data related to the partnership.
CTNM closed at $13.38 on October 9, 2026, prior to the session's sharp decline. Despite the negative momentum, analysts highlighted the long-term potential for the drug PIPE-791 in treating idiopathic pulmonary fibrosis.